Most of the conversation about retatrutide fixates on one number — the ~28.3% average body weight loss reported at 12mg over 80 weeks in the phase 3 TRIUMPH-1 trial. Fair enough; it's the biggest figure any obesity drug has put on the board. But the more interesting question for anyone following retatrutide is why the number is that big. The answer sits in the third receptor — the glucagon arm — and it works on a different side of the energy equation than semaglutide or tirzepatide do.

This is a mechanism piece, not a news bulletin. It's the part of the story that explains the headline result, and the part that also explains retatrutide's known trade-offs.

Retatrutide and the Third Receptor: Burning, Not Just Curbing

Line up the current generation of incretin drugs by how many receptors they hit:

  • Semaglutide (Ozempic, Wegovy) — one: GLP-1.
  • Tirzepatide (Mounjaro, Zepbound) — two: GLP-1 and GIP.
  • Retatrutide — three: GLP-1, GIP and the glucagon receptor.

The first two receptors do broadly similar work: they slow gastric emptying, act on appetite centres in the brain, and improve insulin response. In plain terms, they reduce how much you eat. That's the "curb" side of the ledger, and it's where almost all of the weight loss from the existing approved drugs comes from.

Glucagon receptor agonism is different. Glucagon is best known as insulin's counterpart — the hormone that tells the liver to release glucose when blood sugar drops. But it also has metabolic effects that have interested obesity researchers for decades: it increases energy expenditure and promotes fat oxidation in the liver. In other words, it works on the output side rather than the input side.

That's the theory behind retatrutide's design. Two receptors reduce intake; the third is intended to lift expenditure and push hepatic fat metabolism, so the two effects stack rather than compete. It is the clearest example so far of a weight-loss drug that isn't relying solely on eating less.

Why This Matters for Interpreting the Results

Understanding the mechanism changes how you read the trial data.

It explains the size of the effect. Adding a mechanism that acts on energy output, rather than simply making the appetite signal louder, is a plausible reason retatrutide's numbers sit above the tirzepatide range rather than just at the top of it. That said — and this is important — no adequately powered head-to-head trial of retatrutide versus tirzepatide has reported. Comparing across separate trials with different populations, durations and run-in protocols is a rough instrument, not proof of superiority.

It explains the side effect profile. If glucagon raises hepatic glucose output, you'd expect a glucose-raising signal to appear somewhere — and in earlier-phase work, glycaemic effects have been one of the closely watched parameters, particularly in people with type 2 diabetes. Increases in heart rate have also been observed across this drug class. Neither of these is a mystery; they're the predictable other side of the mechanism, and they're a large part of why dose titration schedules matter so much. There's more on this in our safety overview.

It explains why the liver is such a focus. Hepatic fat oxidation isn't a side note of glucagon agonism — it's central to it. That's why metabolic liver disease has been an area of intense interest for triple agonists specifically, distinct from general weight-loss benefits.

What Is Still Genuinely Unproven

Being honest about the limits here matters more than the story:

  • The headline TRIUMPH-1 figures have circulated largely via company announcements and conference presentation. Company topline reporting is not the same as a full peer-reviewed publication with complete adverse-event tables, and it should be read as preliminary until the full paper is available.
  • The energy-expenditure explanation is mechanistically sound and supported by preclinical and human pharmacology work, but the precise contribution of the glucagon arm to the total weight loss in humans is not neatly quantified. Nobody has published a clean split of "this much came from eating less, this much from burning more."
  • Longer-term consequences of sustained glucagon receptor agonism — over years rather than the 80-week trial window — are simply not known yet. That's not a criticism; it's the normal state of an investigational drug.

You can read the fuller trial picture on our clinical trials page, and the plain-language background on what retatrutide is.

Where Australia Sits

The regulatory position is unchanged and worth restating plainly: retatrutide is investigational and is not approved by the TGA. Eli Lilly has indicated regulatory filings from 2027, and Australian approval would follow its own TGA timeline after that — it is not automatic and not simultaneous with the US or EU.

The Australian relevance of the mechanism story is mostly this: with roughly 66.8% of Australian adults living with overweight or obesity, and a large share of that group also carrying metabolic liver disease, a drug whose third receptor specifically targets hepatic fat is of more than academic interest here. But no clinical decision should be made today on the strength of a mechanism. For where things stand locally, see our Australia page.

Want the full TRIUMPH-1 publication, the head-to-head data and any TGA movement as it happens? Join the free updates list — one email when something real changes, nothing when it doesn't.

FAQ

What is retatrutide's mechanism of action?

Retatrutide is a single molecule that activates three receptors: GLP-1, GIP and glucagon. The GLP-1 and GIP components mainly reduce appetite and food intake, while the glucagon component is intended to increase energy expenditure and promote fat breakdown in the liver.

Why does retatrutide cause more weight loss than tirzepatide?

The leading explanation is the added glucagon receptor activity, which acts on energy output rather than only on appetite. However, no completed head-to-head trial has directly compared the two drugs, so cross-trial comparisons should be treated as indicative rather than conclusive.

Does the glucagon receptor raise blood sugar?

Glucagon normally signals the liver to release glucose, so a glucose-raising effect is a recognised consideration with glucagon receptor agonism, particularly in people with type 2 diabetes. Trial data to date have been reassuring overall, but this remains one of the parameters monitored most closely.

Is retatrutide approved anywhere yet?

No. Retatrutide remains investigational worldwide and is not approved by the TGA, FDA or EMA. Eli Lilly has signalled regulatory filings from 2027, with any approval decision following after that.

Sources

Disclaimer: This article is general information only and is not medical advice. Retatrutide is an investigational medicine and is not approved by the TGA or any other regulator. Always speak with a qualified Australian health professional about your own circumstances. retatrutide.net.au is an independent information site and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company.